4Gololobov G, Sun M, Paul S. Innate antibody catalysis. Molecular Immunology, 1999; 36(18) : 1215-1222.
5Lavoie TB, Mohan S, Lipschultz CA, et al. Structural differences among monoclonal antibodies with distinct fine specificities and kinetic properties.Molecular Immunol,1999;36(17):1189-1205.
6Penichet ML. Antibody - cytokine fusion proteins for the therapy of cancer. J Immunol Methods,2001;248(1):91-101.
7Lanning D, Zhu X, Zhai SK,et al.Development of the antibody repertoire in rabbit:gut-associated lymphoid tissue,microbes and selection.Immunological Reviews,2000;175(2);214-228.
8Koehler G, Milestem C. Continuous cultures d fused cells secreting antibody of predefined specificity. Nature, 1975;256(5517)495- 497.
9Serafini AN.From monoclonal antibodies to peptides and molecular recognition units:an overview.J Nuclear Medicine, 1993;34(3) : 533- 536.
10Steplewski Z. Biological activity of human - mouse IgGl, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with antitumor specificity.Proc Natl Acad Sci USA, 1988;85(13) :4852-4856.
2Bang Y J,Van Cutsem E,Feyereislova A,et al.Trastuzumabin combination with chemotherapy versus chemotherapy alonefor treatment of HER2-positive advanced gastric or gastro-oe-sophageal junction cancer(ToGA):aphase 3,open-label,ran-domised controlled trial. The Lancet . 2010
3Cavahee W K,White R L.The genetic basis of cancer. Scientific American . 1995
